Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma
Bengaluru & Hyderabad, India; October 8, 2024: Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective
September 30- October 3, 2024, Discovery on Target
1) Discovery and Development of pan-KRAS Degraders for Cancer Therapyn 2) Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical Cancer Models
Indian Council of Medical Research Signs Memorandum of Agreements with Industry and Academic Partners to Advance First-in-Human Phase 1 Clinical Trials
A key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens: Union Minister Shri J P Nadda The partnership marks a pivotal step towards establishing India’s
September 1-5, 2024, XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024)
1) Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072) April 5- 10, 2024, AACR Conference
1) SMARCA 2/4 Degraders Relieve The Differentiation Block In AML via Changes In Chromatin Looping and Accessibility2) Paralogue Selectivity p300 Degraders Induce Synthetic Lethality in Pre-Clinical Models of CBP- Deficient